NSCLC RET

The different mechanisms of resistance to RET therapies & strategies to target these mechanismsПодробнее

CRSF 7th Masterclass | Resistance to RET TKI & Post-Resistance Therapy by Dr. Vibhor SharmaПодробнее

Are there any new treatment options for RET + NSCLC patients?Подробнее

Dr Massarelli on Using Selpercatinib and Pralsetinib in Treating Advanced Non-Small Cell Lung CancerПодробнее

First-Line Selpercatinib Chemotherapy + Pembrolizumab in RET+ NSCLC | Dr. Pradeep Ventrapati | CRSFПодробнее

RET融合遺伝子陽性肺がん　アップデート【動画でわかる肺がん治療の最前線】Подробнее

RET Inhibitors for RET-Altered Non-Small Cell Lung Cancer: Identification, Treatment, and Practic...Подробнее

CRSF 7th Masterclass | RET Mutation Interpretation in Lung Cancer by Dr. Trupti Pai | Day 3Подробнее

RET Inhibitors in Advanced NSCLC, Tanya Guel-Pérez, MDПодробнее

Are RET inhibitors recommended as first-line therapy for RET-fusion positive metastatic NSCLC?Подробнее

Highlights on selpercatinib in RET fusion-positive NSCLC: The LIBRETTO-431 studyПодробнее

RET Fusion Treatment: Selpercatinib - Targeted Therapies in Lung Cancer 2023Подробнее

Decision-Making in Testing and Treatment of RET-Altered Lung and Thyroid CancersПодробнее

Rare Fusions in NSCLC: RET - Targeted Therapies in Lung Cancer 2023Подробнее

Concerning Kinases: Therapeutic Considerations for RET Rearranged NSCLCПодробнее

Krebsmutationen: RET-Fusionen - Wie schnell geht das hier denn bitte?Подробнее

Gestione del carcinoma midollare della tiroide con mutazione RET in prima lineaПодробнее

Selpercatinib benefit, with or without pembro, in first-line advanced RET fusion-positive NSCLCПодробнее

2023 Best of Lung: Targeted Therapies in Lung CancerПодробнее

Q&A: RET Fusion, Lobectomy, and Chemo: Risk of Recurrence? - Targeted Therapies in Lung Cancer 2023Подробнее